Literature DB >> 7923383

In vitro immune responsiveness of rats lacking active dipeptidylpeptidase IV.

M C Coburn1, D C Hixson, J S Reichner.   

Abstract

DPPIV (CD26) is a cell surface serine exoprotease recently described as a T cell activation molecule. A substrain of German Fischer 344 rats expressing a truncated, inactive form of DPPIV were used to determine whether the absence of enzymatic activity affected the overall immunological competence of these rats as compared to American Fischer 344 rats that express normal levels of DPPIV activity. The proliferative responses of splenic leukocytes obtained from both strains of rats were assessed in vitro following stimulation by T cell (Con A), B cell (LPS), and T and B cell (PWM) mitogens. In addition, proliferation was determined in the presence and absence of N-MMA, an inhibitor of nitric oxide production which is known to be a potent regulator of lymphocyte proliferation in vitro. Finally, the ability of these rats to produce a secondary response to KLH-primed lymphocytes was compared. No significant differences were found between the magnitude of either the mitogen or antigen-driven responses of immune cells obtained from American and German rats. The response to restimulation by KLH resulted in equivalent levels of KLH-specific immunoglobulin and IFN-gamma production as well. Taken together, these findings demonstrate that the proteolytic activity of DPPIV may not be necessary for the generation of immune competence or that in the absence of functional DPPIV, German Fischer rats have developed a compensatory proteolytic mechanism.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7923383     DOI: 10.1006/cimm.1994.1275

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  7 in total

Review 1.  Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.

Authors:  C Klemann; L Wagner; M Stephan; S von Hörsten
Journal:  Clin Exp Immunol       Date:  2016-05-13       Impact factor: 4.330

2.  Circulating CD26 is negatively associated with inflammation in human and experimental arthritis.

Authors:  Nathalie Busso; Nicolai Wagtmann; Christian Herling; Veronique Chobaz-Péclat; Angelika Bischof-Delaloye; Alexander So; Eric Grouzmann
Journal:  Am J Pathol       Date:  2005-02       Impact factor: 4.307

Review 3.  The Multiple Biological Functions of Dipeptidyl Peptidase-4 in Bone Metabolism.

Authors:  Qiu Yang; Bing Fu; Dan Luo; Haibo Wang; Hongyi Cao; Xiang Chen; Li Tian; Xijie Yu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-02       Impact factor: 6.055

4.  CD26/dipeptidyl peptidase 4-deficiency alters thymic emigration patterns and leukcocyte subsets in F344-rats age-dependently.

Authors:  C Klemann; J Schade; R Pabst; S Leitner; J Stiller; S von Hörsten; M Stephan
Journal:  Clin Exp Immunol       Date:  2008-12-01       Impact factor: 4.330

5.  Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration through incretin-dependent and -independent pathways.

Authors:  Su-Jin Kim; Cuilan Nian; Christopher H S McIntosh
Journal:  Diabetes       Date:  2010-04-05       Impact factor: 9.461

6.  Dipeptidyl peptidase IV on activated T cells as a target molecule for therapy of rheumatoid arthritis.

Authors:  Y N Williams; H Baba; S Hayashi; H Ikai; T Sugita; S Tanaka; N Miyasaka; T Kubota
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

7.  Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses.

Authors:  Kalpit A Vora; Gene Porter; Roche Peng; Yan Cui; Kellyann Pryor; George Eiermann; Dennis M Zaller
Journal:  BMC Immunol       Date:  2009-04-09       Impact factor: 3.615

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.